The nociceptin/orphanin FQ (NOP) receptor antagonist J‐113397 enhances the effects of levodopa in the MPTP‐lesioned nonhuman primate model of Parkinson's disease
Identifieur interne : 002578 ( Main/Curation ); précédent : 002577; suivant : 002579The nociceptin/orphanin FQ (NOP) receptor antagonist J‐113397 enhances the effects of levodopa in the MPTP‐lesioned nonhuman primate model of Parkinson's disease
Auteurs : Naomi P. Visanji [Canada] ; Rob M. A. De Bie [Canada, Pays-Bas] ; Tom H. Johnston [Canada] ; Andrew C. Mccreary [Pays-Bas] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada]Source :
- Movement Disorders [ 0885-3185 ] ; 2008-10-15.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Analysis of Variance, Animals, Antiparkinson Agents (therapeutic use), Benzimidazoles (therapeutic use), Callithrix, Disability Evaluation, Disease Models, Animal, Drug Synergism, Dyskinesia, Levodopa, Levodopa (therapeutic use), MPTP, MPTP Poisoning (drug therapy), Models, N/OFQ receptor, Nervous system diseases, Nociceptin, Opioid Peptides (antagonists & inhibitors), Parkinson disease, Piperidines (therapeutic use), Primates, Time Factors, dyskinesia, levodopa, marmoset, nociceptin/orphanin FQ.
- MESH :
- chemical , antagonists & inhibitors : Opioid Peptides.
- chemical , therapeutic use : Antiparkinson Agents, Benzimidazoles, Levodopa, Piperidines.
- drug therapy : MPTP Poisoning.
- Analysis of Variance, Animals, Callithrix, Disability Evaluation, Disease Models, Animal, Drug Synergism, Time Factors.
Abstract
The anti‐parkinsonian and levodopa‐sparing potential of the nociceptin/orphanin FQ receptor (NOP) antagonist J‐113397 has been demonstrated in rodent models of Parkinson's disease. Here, we describe the levodopa‐sparing potential of J‐113397 in MPTP‐lesioned marmosets. Coadministration of J‐113397 (30 mg/kg) with a sub‐therapeutic dose of levodopa (12.5 mg/kg) produced an anti‐parkinsonian action equivalent to that of a therapeutic dose of levodopa. However, these effects were accompanied by an equivalent level of dyskinesia. The actions of NOP antagonists seen in rodents translate to nonhuman primates. However, the present study raises the possibility that these levodopa‐sparing benefits may be offset by a propensity to exacerbate dyskinesia. © 2008 Movement Disorder Society
Url:
DOI: 10.1002/mds.22086
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001416
- to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :001416
- to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001134
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002071
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :002071
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002034
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :002292
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :002292
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002292
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :003156
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001077
- to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :001C42
- to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001054
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :003662
Links to Exploration step
ISTEX:94F291E4B0C8056170DA9F7765D5C13E4056C439Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The nociceptin/orphanin FQ (NOP) receptor antagonist J‐113397 enhances the effects of levodopa in the MPTP‐lesioned nonhuman primate model of Parkinson's disease</title>
<author><name sortKey="Visanji, Naomi P" sort="Visanji, Naomi P" uniqKey="Visanji N" first="Naomi P." last="Visanji">Naomi P. Visanji</name>
</author>
<author><name sortKey="De Bie, Rob M A" sort="De Bie, Rob M A" uniqKey="De Bie R" first="Rob M. A." last="De Bie">Rob M. A. De Bie</name>
</author>
<author><name sortKey="Johnston, Tom H" sort="Johnston, Tom H" uniqKey="Johnston T" first="Tom H." last="Johnston">Tom H. Johnston</name>
</author>
<author><name sortKey="Mccreary, Andrew C" sort="Mccreary, Andrew C" uniqKey="Mccreary A" first="Andrew C." last="Mccreary">Andrew C. Mccreary</name>
</author>
<author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
</author>
<author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:94F291E4B0C8056170DA9F7765D5C13E4056C439</idno>
<date when="2008" year="2008">2008</date>
<idno type="doi">10.1002/mds.22086</idno>
<idno type="url">https://api.istex.fr/document/94F291E4B0C8056170DA9F7765D5C13E4056C439/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001416</idno>
<idno type="wicri:Area/Istex/Curation">001416</idno>
<idno type="wicri:Area/Istex/Checkpoint">001134</idno>
<idno type="wicri:doubleKey">0885-3185:2008:Visanji N:the:nociceptin:orphanin</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:18759357</idno>
<idno type="wicri:Area/PubMed/Corpus">002071</idno>
<idno type="wicri:Area/PubMed/Curation">002071</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002034</idno>
<idno type="wicri:Area/Ncbi/Merge">002292</idno>
<idno type="wicri:Area/Ncbi/Curation">002292</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002292</idno>
<idno type="wicri:Area/Main/Merge">003156</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:08-0522213</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001077</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001C42</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001054</idno>
<idno type="wicri:doubleKey">0885-3185:2008:Visanji N:the:nociceptin:orphanin</idno>
<idno type="wicri:Area/Main/Merge">003662</idno>
<idno type="wicri:Area/Main/Curation">002578</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The nociceptin/orphanin FQ (NOP) receptor antagonist J‐113397 enhances the effects of levodopa in the MPTP‐lesioned nonhuman primate model of Parkinson's disease</title>
<author><name sortKey="Visanji, Naomi P" sort="Visanji, Naomi P" uniqKey="Visanji N" first="Naomi P." last="Visanji">Naomi P. Visanji</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Toronto Western Research Institute, Toronto</wicri:regionArea>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="De Bie, Rob M A" sort="De Bie, Rob M A" uniqKey="De Bie R" first="Rob M. A." last="De Bie">Rob M. A. De Bie</name>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Neurology, University of Toronto, Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
<affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Current Address: Department of Neurology, Academic Medical Center, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Johnston, Tom H" sort="Johnston, Tom H" uniqKey="Johnston T" first="Tom H." last="Johnston">Tom H. Johnston</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Toronto Western Research Institute, Toronto</wicri:regionArea>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mccreary, Andrew C" sort="Mccreary, Andrew C" uniqKey="Mccreary A" first="Andrew C." last="Mccreary">Andrew C. Mccreary</name>
<affiliation wicri:level="1"><country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Solvay Pharmaceuticals Research Laboratories, Weesp</wicri:regionArea>
<wicri:noRegion>Weesp</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Toronto Western Research Institute, Toronto</wicri:regionArea>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Toronto Western Research Institute, Toronto</wicri:regionArea>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Neurology, University of Toronto, Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2008-10-15">2008-10-15</date>
<biblScope unit="vol">23</biblScope>
<biblScope unit="issue">13</biblScope>
<biblScope unit="page" from="1922">1922</biblScope>
<biblScope unit="page" to="1925">1925</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">94F291E4B0C8056170DA9F7765D5C13E4056C439</idno>
<idno type="DOI">10.1002/mds.22086</idno>
<idno type="ArticleID">MDS22086</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Analysis of Variance</term>
<term>Animals</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Benzimidazoles (therapeutic use)</term>
<term>Callithrix</term>
<term>Disability Evaluation</term>
<term>Disease Models, Animal</term>
<term>Drug Synergism</term>
<term>Dyskinesia</term>
<term>Levodopa</term>
<term>Levodopa (therapeutic use)</term>
<term>MPTP</term>
<term>MPTP Poisoning (drug therapy)</term>
<term>Models</term>
<term>N/OFQ receptor</term>
<term>Nervous system diseases</term>
<term>Nociceptin</term>
<term>Opioid Peptides (antagonists & inhibitors)</term>
<term>Parkinson disease</term>
<term>Piperidines (therapeutic use)</term>
<term>Primates</term>
<term>Time Factors</term>
<term>dyskinesia</term>
<term>levodopa</term>
<term>marmoset</term>
<term>nociceptin/orphanin FQ</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Opioid Peptides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Benzimidazoles</term>
<term>Levodopa</term>
<term>Piperidines</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>MPTP Poisoning</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Analysis of Variance</term>
<term>Animals</term>
<term>Callithrix</term>
<term>Disability Evaluation</term>
<term>Disease Models, Animal</term>
<term>Drug Synergism</term>
<term>Time Factors</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Dyskinésie</term>
<term>Lévodopa</term>
<term>Maladie de Parkinson</term>
<term>Modèle</term>
<term>Nociceptine</term>
<term>Pathologie du système nerveux</term>
<term>Primates</term>
<term>Récepteur N/OFQ</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The anti‐parkinsonian and levodopa‐sparing potential of the nociceptin/orphanin FQ receptor (NOP) antagonist J‐113397 has been demonstrated in rodent models of Parkinson's disease. Here, we describe the levodopa‐sparing potential of J‐113397 in MPTP‐lesioned marmosets. Coadministration of J‐113397 (30 mg/kg) with a sub‐therapeutic dose of levodopa (12.5 mg/kg) produced an anti‐parkinsonian action equivalent to that of a therapeutic dose of levodopa. However, these effects were accompanied by an equivalent level of dyskinesia. The actions of NOP antagonists seen in rodents translate to nonhuman primates. However, the present study raises the possibility that these levodopa‐sparing benefits may be offset by a propensity to exacerbate dyskinesia. © 2008 Movement Disorder Society</div>
</front>
</TEI>
<double idat="0885-3185:2008:Visanji N:the:nociceptin:orphanin"><INIST><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">The Nociceptin/Orphanin FQ (NOP) Receptor Antagonist J-113397 Enhances the Effects of Levodopa in the MPTP-Lesioned Nonhuman Primate Model of Parkinson's Disease</title>
<author><name sortKey="Visanji, Naomi P" sort="Visanji, Naomi P" uniqKey="Visanji N" first="Naomi P." last="Visanji">Naomi P. Visanji</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Toronto Western Research Institute</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto Western Research Institute</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="De Bie, Rob M A" sort="De Bie, Rob M A" uniqKey="De Bie R" first="Rob M. A." last="De Bie">Rob M. A. De Bie</name>
<affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Division of Neurology, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author><name sortKey="Johnston, Tom H" sort="Johnston, Tom H" uniqKey="Johnston T" first="Tom H." last="Johnston">Tom H. Johnston</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Toronto Western Research Institute</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto Western Research Institute</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mccreary, Andrew C" sort="Mccreary, Andrew C" uniqKey="Mccreary A" first="Andrew C." last="Mccreary">Andrew C. Mccreary</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Solvay Pharmaceuticals Research Laboratories</s1>
<s2>Weesp</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
<wicri:noRegion>Solvay Pharmaceuticals Research Laboratories</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Toronto Western Research Institute</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto Western Research Institute</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Toronto Western Research Institute</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto Western Research Institute</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Division of Neurology, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0522213</idno>
<date when="2008">2008</date>
<idno type="stanalyst">PASCAL 08-0522213 INIST</idno>
<idno type="RBID">Pascal:08-0522213</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001077</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001C42</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001054</idno>
<idno type="wicri:doubleKey">0885-3185:2008:Visanji N:the:nociceptin:orphanin</idno>
<idno type="wicri:Area/Main/Merge">003662</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">The Nociceptin/Orphanin FQ (NOP) Receptor Antagonist J-113397 Enhances the Effects of Levodopa in the MPTP-Lesioned Nonhuman Primate Model of Parkinson's Disease</title>
<author><name sortKey="Visanji, Naomi P" sort="Visanji, Naomi P" uniqKey="Visanji N" first="Naomi P." last="Visanji">Naomi P. Visanji</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Toronto Western Research Institute</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto Western Research Institute</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="De Bie, Rob M A" sort="De Bie, Rob M A" uniqKey="De Bie R" first="Rob M. A." last="De Bie">Rob M. A. De Bie</name>
<affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Division of Neurology, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author><name sortKey="Johnston, Tom H" sort="Johnston, Tom H" uniqKey="Johnston T" first="Tom H." last="Johnston">Tom H. Johnston</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Toronto Western Research Institute</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto Western Research Institute</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mccreary, Andrew C" sort="Mccreary, Andrew C" uniqKey="Mccreary A" first="Andrew C." last="Mccreary">Andrew C. Mccreary</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Solvay Pharmaceuticals Research Laboratories</s1>
<s2>Weesp</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
<wicri:noRegion>Solvay Pharmaceuticals Research Laboratories</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Toronto Western Research Institute</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto Western Research Institute</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Toronto Western Research Institute</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto Western Research Institute</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Division of Neurology, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dyskinesia</term>
<term>Levodopa</term>
<term>Models</term>
<term>N/OFQ receptor</term>
<term>Nervous system diseases</term>
<term>Nociceptin</term>
<term>Parkinson disease</term>
<term>Primates</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Dyskinésie</term>
<term>Pathologie du système nerveux</term>
<term>Récepteur N/OFQ</term>
<term>Lévodopa</term>
<term>Primates</term>
<term>Modèle</term>
<term>Nociceptine</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The anti-parkinsonian and levodopa-sparing potential of the nociceptin/orphanin FQ receptor (NOP) antagonist J-113397 has been demonstrated in rodent models of Parkinson's disease. Here, we describe the levodopa-sparing potential of J-113397 in MPTP-lesioned marmosets. Coadministration of J-113397 (30 mg/kg) with a sub-therapeutic dose of levodopa (12.5 mg/kg) produced an anti-parkinsonian action equivalent to that of a therapeutic dose of levodopa. However, these effects were accompanied by an equivalent level of dyskinesia. The actions of NOP antagonists seen in rodents translate to nonhuman primates. However, the present study raises the possibility that these levodopa-sparing benefits may be offset by a propensity to exacerbate dyskinesia.</div>
</front>
</TEI>
</INIST>
<ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The nociceptin/orphanin FQ (NOP) receptor antagonist J‐113397 enhances the effects of levodopa in the MPTP‐lesioned nonhuman primate model of Parkinson's disease</title>
<author><name sortKey="Visanji, Naomi P" sort="Visanji, Naomi P" uniqKey="Visanji N" first="Naomi P." last="Visanji">Naomi P. Visanji</name>
</author>
<author><name sortKey="De Bie, Rob M A" sort="De Bie, Rob M A" uniqKey="De Bie R" first="Rob M. A." last="De Bie">Rob M. A. De Bie</name>
</author>
<author><name sortKey="Johnston, Tom H" sort="Johnston, Tom H" uniqKey="Johnston T" first="Tom H." last="Johnston">Tom H. Johnston</name>
</author>
<author><name sortKey="Mccreary, Andrew C" sort="Mccreary, Andrew C" uniqKey="Mccreary A" first="Andrew C." last="Mccreary">Andrew C. Mccreary</name>
</author>
<author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
</author>
<author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:94F291E4B0C8056170DA9F7765D5C13E4056C439</idno>
<date when="2008" year="2008">2008</date>
<idno type="doi">10.1002/mds.22086</idno>
<idno type="url">https://api.istex.fr/document/94F291E4B0C8056170DA9F7765D5C13E4056C439/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001416</idno>
<idno type="wicri:Area/Istex/Curation">001416</idno>
<idno type="wicri:Area/Istex/Checkpoint">001134</idno>
<idno type="wicri:doubleKey">0885-3185:2008:Visanji N:the:nociceptin:orphanin</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:18759357</idno>
<idno type="wicri:Area/PubMed/Corpus">002071</idno>
<idno type="wicri:Area/PubMed/Curation">002071</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002034</idno>
<idno type="wicri:Area/Ncbi/Merge">002292</idno>
<idno type="wicri:Area/Ncbi/Curation">002292</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002292</idno>
<idno type="wicri:Area/Main/Merge">003156</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The nociceptin/orphanin FQ (NOP) receptor antagonist J‐113397 enhances the effects of levodopa in the MPTP‐lesioned nonhuman primate model of Parkinson's disease</title>
<author><name sortKey="Visanji, Naomi P" sort="Visanji, Naomi P" uniqKey="Visanji N" first="Naomi P." last="Visanji">Naomi P. Visanji</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Toronto Western Research Institute, Toronto</wicri:regionArea>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="De Bie, Rob M A" sort="De Bie, Rob M A" uniqKey="De Bie R" first="Rob M. A." last="De Bie">Rob M. A. De Bie</name>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Neurology, University of Toronto, Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
<affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Current Address: Department of Neurology, Academic Medical Center, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Johnston, Tom H" sort="Johnston, Tom H" uniqKey="Johnston T" first="Tom H." last="Johnston">Tom H. Johnston</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Toronto Western Research Institute, Toronto</wicri:regionArea>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mccreary, Andrew C" sort="Mccreary, Andrew C" uniqKey="Mccreary A" first="Andrew C." last="Mccreary">Andrew C. Mccreary</name>
<affiliation wicri:level="1"><country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Solvay Pharmaceuticals Research Laboratories, Weesp</wicri:regionArea>
<wicri:noRegion>Weesp</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Toronto Western Research Institute, Toronto</wicri:regionArea>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Toronto Western Research Institute, Toronto</wicri:regionArea>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Neurology, University of Toronto, Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2008-10-15">2008-10-15</date>
<biblScope unit="vol">23</biblScope>
<biblScope unit="issue">13</biblScope>
<biblScope unit="page" from="1922">1922</biblScope>
<biblScope unit="page" to="1925">1925</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">94F291E4B0C8056170DA9F7765D5C13E4056C439</idno>
<idno type="DOI">10.1002/mds.22086</idno>
<idno type="ArticleID">MDS22086</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Analysis of Variance</term>
<term>Animals</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Benzimidazoles (therapeutic use)</term>
<term>Callithrix</term>
<term>Disability Evaluation</term>
<term>Disease Models, Animal</term>
<term>Drug Synergism</term>
<term>Levodopa (therapeutic use)</term>
<term>MPTP</term>
<term>MPTP Poisoning (drug therapy)</term>
<term>Opioid Peptides (antagonists & inhibitors)</term>
<term>Piperidines (therapeutic use)</term>
<term>Time Factors</term>
<term>dyskinesia</term>
<term>levodopa</term>
<term>marmoset</term>
<term>nociceptin/orphanin FQ</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Opioid Peptides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Benzimidazoles</term>
<term>Levodopa</term>
<term>Piperidines</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>MPTP Poisoning</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Analysis of Variance</term>
<term>Animals</term>
<term>Callithrix</term>
<term>Disability Evaluation</term>
<term>Disease Models, Animal</term>
<term>Drug Synergism</term>
<term>Time Factors</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The anti‐parkinsonian and levodopa‐sparing potential of the nociceptin/orphanin FQ receptor (NOP) antagonist J‐113397 has been demonstrated in rodent models of Parkinson's disease. Here, we describe the levodopa‐sparing potential of J‐113397 in MPTP‐lesioned marmosets. Coadministration of J‐113397 (30 mg/kg) with a sub‐therapeutic dose of levodopa (12.5 mg/kg) produced an anti‐parkinsonian action equivalent to that of a therapeutic dose of levodopa. However, these effects were accompanied by an equivalent level of dyskinesia. The actions of NOP antagonists seen in rodents translate to nonhuman primates. However, the present study raises the possibility that these levodopa‐sparing benefits may be offset by a propensity to exacerbate dyskinesia. © 2008 Movement Disorder Society</div>
</front>
</TEI>
</ISTEX>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002578 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 002578 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Curation |type= RBID |clé= ISTEX:94F291E4B0C8056170DA9F7765D5C13E4056C439 |texte= The nociceptin/orphanin FQ (NOP) receptor antagonist J‐113397 enhances the effects of levodopa in the MPTP‐lesioned nonhuman primate model of Parkinson's disease }}
This area was generated with Dilib version V0.6.23. |